Clinical outcomes of hospitalized Covid 19 pneumonia patients with and
without metabolic syndrome.
Abstract
Aims: Metabolic Syndrome has become the greatest health hazard in the
modern world, along with infectious diseases. We aimed to evaluate the
effects of metabolic syndrome on disease course, laboratory values and
mortality in patients with COVID 19 pneumonia. Methods: COVID 19
pneumonia patients with and without metabolic syndrome were compared in
terms of laboratory parameters, clinical results and mortality rates
retrospectively. Results: A total of 194 patients hospitalized with
COVID 19 pneumonia (with and without metabolic syndrome n = 93 and 101,
respectively) were included in the study. Patients with metabolic
syndrome had lower oxygen saturation at the time of admission (88.76 vs
93.66 p <0.0001), higher neutrophil (5.85 vs 4.81 p = 0.02)
and CRP levels (88.36 vs 62.93 p = 0.009) and COVID 19 involvement was
more common in lung tomography (12.3 vs 7.7 p <0.0001). Total
length of stay (12.3 vs 6.5 days p <0.0001) and clinical
length of stay (7.8 vs 5.9 days p = 0.003) were longer in patients with
metabolic syndrome. Requirement of intensive care (45.2% vs 4.9% p
<0.0001) and mortality rates (24.7% vs 0.9% p
<0.0001) were higher in patients with metabolic syndrome.
Presence of metabolic syndrome (OR 32.86, 95% CI 4.34 to 249
p<0.05) were significantly associated with increased
mortality. Discussion and conclusion: Our results demonstrated that
patients with metabolic syndrome that were hospitalized with COVID 19
pneumonia had significantly higher mortality and intensive care
requirement. They have lower oxygen saturations, higher CRP levels and
more widespread radiological involvement. Keywords: Covid 19 - Metabolic
syndrome – Pneumonia - Mortality